I am a healthcare professional

Notice


Welcome to MEDICALLY. This website is a non-promotional international resource intended to facilitate transparent scientific exchange regarding developments in medical research and disease management. It is intended for healthcare professionals outside the United Kingdom (UK) and Australia. The content on this website may include scientific information about experimental or investigational compounds, indications and services that are not approved or valid in your jurisdiction. Registration status and prescribing information of medicinal products may differ between countries. Roche and Genentech do not support, endorse or recommend the unapproved use of any compound or service in your jurisdiction, including those discussed on this website.


Please refer to local product information for any medicinal products mentioned. Information available on this website does not constitute professional medical advice, and Roche and Genentech accept no responsibility for access to or use of the same. Healthcare professionals outside the US are required to register and log-in to access the full range of content available on this website.


By clicking on one of the healthcare professional buttons below, you acknowledge you have read and understood this message and that you are requesting access to MEDICALLY. If you are not a healthcare professional, please use the other links below to access information relevant to you.


Cookies


We use cookies on this site to enable the site to function properly and to enhance your user experience. Cookies are files stored in your browser, which most websites use to personalize your web experience. Your information will only be used to provide information that is relevant to you. It will not be used for any other purpose. If you wish to restrict or block cookies, which are set on your device, then you can do this through your browser settings.


You can find out more about cookies by browsing our Privacy Policy.

 

I am a healthcare professional
(outside the UK) and Australia:

Not a healthcare professional? For individuals outside the US, browse Roche's patient website or roche.com. For individuals in the US, browse gene.com.

External site

By following this link, you are leaving Medically and entering a website that is not owned or controlled by Roche. Roche does not take any responsibility for access to or use of this website, nor for any content therein.

Leave site
Roche and Genentech at

Retina Society 2022

-
Coming soon
04:12 PM
Duration 6mins Huntington Ballroom
Efficacy, Durability, and Safety of Faricimab in Diabetic Macular Edema: 2-Year Results From the Phase 3 YOSEMITE and RHINE Trials
Khurana R, Wells J, Baumal C, Danzig C, Murata T, Schlottmann P, Lin H, Mohan S, Silverman D, Tang Y, Haskova Z

Sign up or login to unlock the full suite of MEDICALLY features

Add to calendar
11:45 AM
Duration 3mins Huntington Ballroom
Design and Rationale of Elevatum: A Phase 4 Trial of Faricimab (VABYSMO) in Underrepresented Patients With Diabetic Macular Edema
Scott A, Amador M, Chang J, Yang M, Stoilov I, Meldorf M, Coney J, Gonzalez L, Cunningham M

Sign up or login to unlock the full suite of MEDICALLY features

Add to calendar
07:38 AM
Duration 4mins Huntington Ballroom
Increased Central Foveal Thickness Fluctuations are Associated with Less Visual Gains in Patients With Central Retinal Vein Occlusion
Kuriyan A, Chiang A, Regillo C, Yonekawa Y, Ho A, Hsu J, Garg S, Yankovskaya Y, Blotner S, Stoilov I, Starr M

Sign up or login to unlock the full suite of MEDICALLY features

Add to calendar
08:13 AM
Duration 8mins Huntington Ballroom
Efficacy, Safety, and Durability of Faricimab in Neovascular Age-Related Macular Degeneration: Year 2 Results From the Phase 3 TENAYA and LUCERNE Trials
Lim J, Silverman D, Swaminathan B, Patel V, Lin H, Willis J, Kotecha A

Sign up or login to unlock the full suite of MEDICALLY features

Add to calendar
08:21 AM
Duration 3mins Huntington Ballroom
Faricimab in Neovascular Age-Related Macular Degeneration: Year 2 Patient Case Profiles From the Phase 3 TENAYA and LUCERNE Trials
London N, Pearce, I, Figueroa MS, Silverman D, Swaminathan B, Patel V, Lin H, Willis JR, Kotecha A

Sign up or login to unlock the full suite of MEDICALLY features

Add to calendar
08:30 AM
Duration 4mins Huntington Ballroom
Overview of Faricimab safety profile from the four Phase 3 studies in nAMD and DME through 2 years
Jaffe G, Kardatzke D, Kotecha A, Steeples L, Willis J, Ives J

Sign up or login to unlock the full suite of MEDICALLY features

Add to calendar
08:34 AM
Duration 4mins Huntington Ballroom
Intraocular Suppression of VEGF-A and Ang-2 Following Intravitreal Administration of Faricimab
Avery R, Stoilov I, Bogman K, Diack C

Sign up or login to unlock the full suite of MEDICALLY features

Add to calendar
08:42 AM
Duration 4mins Huntington Ballroom
Supplemental Intravitreal Ranibizumab Injections in Patients With the Port Delivery System With Ranibizumab in the Phase 3 Archway Trial for Neovascular Age-Related Macular Degeneration
Pieramici D, Gune S, DeGraaf S, Barteselli G, Heinrich D

Sign up or login to unlock the full suite of MEDICALLY features

Add to calendar
08:56 AM
Duration 4mins Huntington Ballroom
Key Pearls of the Refill-Exchange Procedure for the Port Delivery System With Ranibizumab
Dhoot D, Khanani A, Singh N, Barteselli G, Callaway N, Patel S, Jaycock PD, Malhorta V, Menezes A

Sign up or login to unlock the full suite of MEDICALLY features

Add to calendar
04:17 PM
Duration 5mins Huntington Ballroom
Personalized Treatment Interval Dosing Dynamics Over 2 Years in the Phase 3 YOSEMITE/RHINE Trials of Faricimab in Diabetic Macular Edema
Steinle NC, Jaffe GJ, Gerendas BS, Chakravarthy U,Goldberg RA, Korobelnik JF, Tan CS, Abreu F, Jain N, Tang Y, Camino A, Haskova Z

Sign up or login to unlock the full suite of MEDICALLY features

Add to calendar